Q1 2023 13F Holders as of 31 Mar 2023
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
77,392,610
-
Number of holders
-
66
-
Total 13F shares, excl. options
-
24,614,198
-
Shares change
-
+24,614,198
-
Total reported value, excl. options
-
$385,431,208
-
Value change
-
+$385,431,208
-
Number of buys
-
66
-
Price
-
$15.66
Significant Holders of Mineralys Therapeutics, Inc. - Common Stock (MLYS) as of Q1 2023
66 filings reported holding MLYS - Mineralys Therapeutics, Inc. - Common Stock as of Q1 2023.
Mineralys Therapeutics, Inc. - Common Stock (MLYS) has 66 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 24,614,198 shares
of 77,392,610 outstanding shares and own 32% of the company stock.
Largest 10 shareholders include Samsara BioCapital, LLC (4,519,361 shares), RA CAPITAL MANAGEMENT, L.P. (3,178,476 shares), ADAMS STREET PARTNERS LLC (2,419,501 shares), SR ONE CAPITAL MANAGEMENT, LP (1,794,600 shares), Avidity Partners Management LP (1,263,800 shares), Rock Springs Capital Management LP (1,167,492 shares), RTW INVESTMENTS, LP (922,100 shares), BlackRock Inc. (749,689 shares), DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) (729,021 shares), and Laurion Capital Management LP (675,136 shares).
This table shows the top 66 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.